Science Current Events | Science News | Brightsurf.com
 

Nursing home residents at heightened risk of falling in the days following

July 18, 2011
Increased surveillance over 48-hour period may decrease falls

BOSTON-Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.

Published online in the Journal of Gerontology: Medical Sciences, the study found that nursing home residents have a fivefold increased risk of falling within two days of a new prescription for or an increased dose of a non-SSRI (selective serotonin reuptake inhibitor) antidepressant such as bupropion or venlafaxine. The findings suggest that nursing home staff should closely monitor these residents following a prescription change to prevent potential falls.

"Our results," says lead author Sarah D. Berry, M.D., M.P.H., a scientist at the Institute for Aging Research, "identify the days following a new prescription or increased dose of a non-SSRI antidepressant as a window of time associated with a particularly high risk of falling among nursing home residents."

The risk of falls, she says, may be due to acute cognitive or motor effects that have not yet been fully investigated. Certain non-SSRIs, such as trazodone, can cause postural hypotension, a dramatic decrease in blood pressure upon standing that may contribute to falls. Other non-SSRIs, like venlafaxine, can cause sedation and coordination problems that may lead to falls.

According to some estimates, more than one-third of the country's nearly 1.6 million nursing home residents take some type of antidepressant medication. Several previous studies have implicated antidepressants, including both SSRIs, such as paroxetine and sertraline, and non-SSRIs, as a risk factor for falls, especially among older adults; however, it is unclear if the risk accrues during the duration of use or if there are acute risks associated with the initiation or change in dose of a prescription.

Both tricyclic antidepressants and SSRIs, the most commonly prescribed antidepressant medications, have been associated with up to a sixfold increased risk of falls among nursing home residents in other studies. Newer drugs, including serotonin-norepinephrine reuptake inhibitors, may also be associated with falls risk. Regardless, says Dr. Berry, "these drugs are effective at treating the symptoms of depression, and many clinicians are reluctant to withhold their use based solely on a risk for falls."

Although many studies have examined chronic antidepressant use as a risk factor for falls, few have considered the short-term effects of a change in antidepressant prescription. Dr. Berry's study, called a case-crossover study, examined 1,181 residents of a Boston-area nursing home who fell, comparing the frequency of antidepressant changes during a "hazard" period (1-7 days before a fall) with the frequency of antidepressant changes during a control period (8-14 days before a fall). Information on falls was collected using the facility's federally-mandated computerized incident reports. The risk of falls was greatest within a two-day period of a change in a non-SSRI prescription (either new or existing), while no association was found between SSRIs and falls. The risk of falls diminished each day following the prescription change.

In light of her findings, says Dr. Berry, an instructor in medicine at Harvard Medical School, "nursing home staff should keep a watchful eye on residents in the days following a non-SSRI antidepressant change to prevent falls and clinicians should avoid making changes on weekends or during times when unfamiliar staff is present."

###

The study was funded by a grant from the National Institute on Aging, the Hartford Geriatrics Health Outcomes Research Scholars Awards Program, and the Men's Associates of Hebrew SeniorLife.

Scientists at the Institute for Aging Research seek to transform the human experience of aging by conducting research that will ensure a life of health, dignity and productivity into advanced age. The Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.

Founded in 1903, Hebrew SeniorLife, an affiliate of Harvard Medical School, is a nonprofit, nonsectarian organization devoted to innovative research, health care, education and housing that improves the lives of seniors. For more information, please visit www.hebrewseniorlife.org.

Hebrew SeniorLife Institute for Aging Research


Related Antidepressant Current Events and Antidepressant News Articles


Antidepressants beneficial for women with postnatal depression
Antidepressants are associated with better rates of treatment response and remission for women with postnatal depression, when compared to a placebo, according to a new systematic review by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

Debate: Is the long term use of psychiatric drugs harmful?
The benefits of psychiatric drugs have been exaggerated and the harms underplayed due to poor trial designs, argues one expert in The BMJ. But another expert and a patient contend that the evidence supports the use of these drugs.

Method for determining possible stress marker in blood samples
A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential.

Nail biters, beware: Teeth grinding is next
Anxiety disorders affect approximately one in six adult Americans, according to the National Institute of Mental Health.

Mindfulness-based therapy rather than antidepressants to prevent depression relapse?
Researchers from Plymouth University Peninsula Schools of Medicine and Dentistry are part of a team led by the University of Oxford, who have carried out new research that suggests mindfulness-based cognitive therapy (MBCT) could provide an alternative non-drug treatment for people who do not wish to continue long-term antidepressant treatment.

Mindfulness-based therapy could offer an alternative to antidepressants for preventing depression relapse
Mindfulness-based cognitive therapy (MBCT) could provide an alternative non-drug treatment for people who do not wish to continue long-term antidepressant treatment, suggests new research published in The Lancet.

Wristband that measures rest, activity schedule may help predict response to antidepressants
A wristband that records motion throughout a 24-hour cycle may be an inexpensive, safe way to determine which patients with major depressive disorder will respond best to commonly prescribed drugs such as Prozac.

Babies exposed to narcotic pain relievers more likely to experience withdrawal
Neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in infants following birth, has historically been associated with illicit drug use among pregnant women.

Easing the pain
The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

Common antidepressant increased coronary atherosclerosis in animal model
A commonly prescribed antidepressant caused up to a six-fold increase in atherosclerosis plaque in the coronary arteries of non-human primates, according to a study by researchers at Wake Forest Baptist Medical Center. Coronary artery atherosclerosis is the primary cause of heart attacks.
More Antidepressant Current Events and Antidepressant News Articles

The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction"

The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction"
by M.D. Joseph Glenmullen M.D. (Author)


With the FDA's warning that antidepressants may cause agitation, anxiety, hostility, and even violent or suicidal tendencies, these medications are at the forefront of national legal news. Harvard physician Joseph Glenmullen has led the charge to warn the public that antidepressants are overprescribed, underregulated, and, especially, misunderstood in their side and withdrawal effects. Now he offers a solution!

More than twenty million Americans -- including over one million teens and children -- take one of today's popular antidepressants, such as Paxil, Zoloft, or Effexor. Dr. Glenmullen recognizes the many benefits of antidepressants and prescribes them to his patients, but he is also committed to warning the public of the dangers associated with overprescription. Dr....

The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox

The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox
by Peter R. Breggin (Author)


Known as "the Ralph Nader of psychiatry," Dr. Peter Breggin has been the medical expert in countless court cases involving the use or misuse of psychoactive medications. This unusual position has given him unprecedented access to private pharmaceutical research and correspondence files, information from which informs this straight-talking guide to the most prescribed and controversial category of American drugs: antidepressants. From how these drugs work in the brain to how they treat (or don't treat) depression and obsessive-compulsive, panic, and other disorders; from the documented side and withdrawal effects to what every parent needs to know about antidepressants and teenagers, The Anti-Depressant Fact Book is up-to-the minute and easy-to-access. Hard-hitting and enlightening, every...

The Antidepressant Survival Guide: The Clinically Proven Program to Enhance the Benefits and Beat the Side Effects of Your Medication

The Antidepressant Survival Guide: The Clinically Proven Program to Enhance the Benefits and Beat the Side Effects of Your Medication
by Robert J. Hedaya (Author)


"Now patients can have the best of both worlds -- freedom from depression and freedom from side effects. Dr. Robert Hedaya offers a wealth of wisdom drawn from years of clinical experience, research, and teaching. This book is a much-needed lantern in the darkness."
-- Norman Rosenthal, M.D., author of St. John's Wort: The Herbal Way to Feeling Good

* Restore the vital vitamins, minerals, and hormones necessary to maintain good health.
* Optimize your body's metabolic system.
* Restore your ability to experience pleasure in life.

An estimated twenty-five million Americans take antidepressants to combat depression, but most continue to cope with a host of debilitating side effects that equal, and sometimes outweigh, the medication's obvious benefits. Many doctors...

Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting

Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting
by Michael Banov (Author)


Walks readers with depression through a personalized process to help them make the right choice about starting, staying on, and stopping antidepressants.

The Soft Landing Method for Quitting Antidepressants - How to successfully get off antidepressants the right way, first time

The Soft Landing Method for Quitting Antidepressants - How to successfully get off antidepressants the right way, first time


Completely updated for 2014 with the latest advanced in our understanding of SSRI DiscontinuationEverything you need to know to ensure you have a "soft landing" as you come off antidepressantsA guide to getting off SSRI antidepressants and starting your drug free life again, from Benjamin Kramer, best-selling author of "Brain Renovation".In this clear and concise guide, Benjamin Kramer gives you an easy to implement blueprint for coming off antidepressants such as SSRIs (Selective Serotonin Re-uptake Inhibitors) using a variety of little-known techniques and tips.With a scientifically-designed tapering plan, including the use of certain other drugs and supplements where required, you can avoid coming in for landing too hard and crashing. Done properly, you CAN have a soft landing off...

Medications for Anxiety & Depression - A guide to choosing the antidepressant or anti-anxiety medication that's right for you

Medications for Anxiety & Depression - A guide to choosing the antidepressant or anti-anxiety medication that's right for you


Are you confused about which antidepressant is right for you? Would you like to learn all the important information on all of the antidepressants currently available?All medications are not equal. Just like a carpenter, you need the right tool for the job. Don't just rely on your doctor - take a proactive role in managing your recovery!Unfortunately, doctors tend to be incredibly busy. Sometimes they just don't have the time to get all the details they need to choose the right medication for you. This means that very often, you will just be prescribed the drug that your doctor has the most experience in. This may or may not be the right tool for the job.Depression and anxiety are incredibly varied conditions. Some people are "anxious depressed" whereas others can be more "low...

The Antidepressant Era

The Antidepressant Era
by David Healy (Author)


When we stop at the pharmacy to pick up our Prozac, are we simply buying a drug? Or are we buying into a disease as well? The first complete account of the phenomenon of antidepressants, this authoritative, highly readable book relates how depression, a disease only recently deemed too rare to merit study, has become one of the most common disorders of our day--and a booming business to boot. The Antidepressant Era chronicles the history of psychopharmacology from its inception with the discovery of chlorpromazine in 1951 to current battles over whether these powerful chemical compounds should replace psychotherapy. An expert in both the history and the science of neurochemistry and psychopharmacology, David Healy offers a close-up perspective on early research and clinical...

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial
by Alison Bass (Author)


As the mental health reporter for the Boston Globe, Alison Bass's front-page reporting on conflicts of interest in medical research stunned readers, and her series on sexual misconduct among psychiatrists earned a Pulitzer Prize nomination. Now she turns her investigative skills to a controversial case that exposed the increased suicide rates among adolescents taking antidepressants such as Paxil, Prozac, and Zoloft.

Side Effects tells the tale of a gutsy assistant attorney general who, along with an unlikely whistle-blower at an Ivy League university, uncovered evidence of deception behind one of the most successful drug campaigns in history. Paxil was the world's bestselling antidepressant in 2002. Pediatric prescriptions soared, even though there was no proof that the drug...

Stahl's Illustrated Antidepressants

Stahl's Illustrated Antidepressants
by Stephen M. Stahl (Author)


All of the titles in the Stahl's Illustrated Series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, Third Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images, and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated Series by first...

The Latest Antidepressants: "Must Know" Information About  Vilazodone (Viibryd®),  Levomilnacipran (Fetzima®), Vortioxetine (Brintellix®), and Lurasidone (Latuda®). (Series: Simple and Practical)

The Latest Antidepressants: "Must Know" Information About Vilazodone (Viibryd®), Levomilnacipran (Fetzima®), Vortioxetine (Brintellix®), and Lurasidone (Latuda®). (Series: Simple and Practical)
by Simple and Practical: The Name Says It All.


If a patient comes in on one the newest antidepressants OR you need to try one of them, will you know what is clinically needed or very little about them? If a drug rep tries to “educate” you about one of the newest antidepressants, will you need that education and not know how to separate the facts from the hype? Or will you be an “up-to-date clinician” who has briefly reviewed key issues and can speak confidently about the medication?

Two problems, however. Who has time to read original papers and even complex review articles with dozens of references? Also, even if you took a week off to read the vast amount of data on these antidepressants, unless you are a researcher in this specific area and have some background in biostatistics, it is not easy to interpret the...

© 2015 BrightSurf.com